Patent · US Active

PDE5 compositions and methods for immunotherapy

US11666642B2 · kind B2 · utility

7Cited by

4References

26Claims

0Family size

Assignee

OBSIDIAN THERAPEUTICS, INC. · US

Inventors

Vipin Suri · Belmont, US
Byron DeLaBarre · Arlington, US
Michael N. Gladstone · Cambridge, US
Celeste Richardson · Cambridge, US
Brian Dolinski · Cambridge, US
Abhishek Kulkarni · Brookline, US
Mara Christine Inniss · Beverly, US
Dexue Sun · Cambridge, US
Dan Jun Li · Cambridge, US
Grace Y. Olinger · Cambridge, US
Scott Francis Heller · Stoughton, US

Key dates

Filing date	Feb 1, 2022
Grant date	Jun 6, 2023
Priority date	—
Expiry date	Feb 1, 2042

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.